The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer (NSCLC), according to a new study led by Yale Cancer Center (YCC) researchers.
The findings, from a global randomized phase 3 clinical trial published today in the New England Journal of Medicine, support the U.S. Food and Drug Administration’s approval of the drug for this indication in May.